Masitinib, Free Base (AB-1010, Masatinib, Kinavet, Masivet, CAS 790299-79-5), >99%

LC Laboratories' Product Number M-7007 - Masitinib, Free Base (AB-1010, Masatinib, Kinavet, Masivet, CAS 790299-79-5), >99% - for research use only. Masitinib mesylate (AB1010) is a protein tyrosine kinase inhibitor. In vitro it has greater activity and selectivity than imatinib mesylate against the wild-type c-Kit receptor and the mutated form in the juxtamembrane region. It also inhibits the PDGF and FGFR3 receptors. A placebo-controlled phase III clinical trial of masitinib was performed in the dogs with nonmetastatic recurrent or nonresectable grade II or III mast cell tumors (MCT). Masitinib significantly increased overall time to tumor progression (TTP) compared with placebo, regardless of whether the tumors expressed mutant or wild-type KIT. Masitinib was generally well tolerated, with the most common adverse events being mild or moderate diarrhea or vomiting. Masitinib treatment of patients with imatinib-resistant tumors was encouraging. The safety profile of masitinib at 12mg/kg/day b.i.d. was favorable and compatible with a long-term regimen for the treatment of solid cancers. Masitinib showed an oral bioavailability of ~60% in cats. Masitinib is the active ingredient in the drug product sold under the trade name Kinavet&reg in the U.S, and under the trade name Masivet® in Europe.  This drug is currently approved in at least one country for the treatment of nonresectable Grade II or III cutaneous mast cell tumors in dogs that have not previously received radiotherapy and/or chemotherapy except corticosteroids.  THE MASITINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT KINAVET® NOR MASIVETreg, AND IS FOR RESEARCH USE ONLY.

• Supplier: LC Laboratories
• Product #: M-7007
• Sku #: M-7007_300mg